Skip to content

Study · Randomized controlled trial · n = 64 · 2015

6 results

Intravaginally applied oxytocin improves post-menopausal vaginal atrophy.

Al-Saqi SH, Uvnäs-Moberg K, Jonasson AF

Post reproductive health19 May 2015Cited by 31 (Europe PMC)

PMID25995333 (opens in a new tab)PMCIDPMC4566058 (opens in a new tab)DOI10.1177/2053369115577328 (opens in a new tab)PepBankPUB-25995333
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In post-menopausal women, endometrial thickness did not differ between the oxytocin treatment and placebo groups after seven weeks.

    In plain wordsIn post-menopausal women, vaginal oxytocin did not change endometrial thickness compared with placebo after seven weeks.

    Peptide
    Oxytocin
    Outcome
    No significant changeEndometrial thickness
    Study

    n = 64

    Comparator
    Placebo
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · intravaginal · seven weeksAs given in this study (human).

    Source sentences

    Summary
    The thickness of the endometrium did not differ between the treatment and placebo groups after seven weeks of treatment.
    1 context sentence
    Summary · context
    Sixty four post-menopausal women between February and June 2012 at the Karolinska University Hospital Huddinge/Sweden.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In post-menopausal women, intravaginal oxytocin (vagitocin) 400 IU for seven weeks increased the percentage of superficial cells in vaginal smears.

    In plain wordsIn post-menopausal women, vaginal oxytocin at the higher dose raised the share of mature surface cells in vaginal smears.

    Peptide
    Oxytocin
    Outcome
    IncreaseSuperficial cells in vaginal smears
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 IU · intravaginal · seven weeksAs given in this study (human).

    Measurements

    P value
    0.0288
    superficial cells, 400 IU

    Source sentences

    Summary
    The percentage of superficial cells in the vaginal smears and the maturation values were significantly increased after seven weeks of treatment with vagitocin 400 IU (p = 0.0288 and p = 0.0002, respectively).
    1 context sentence
    Summary · context
    Sixty four post-menopausal women between February and June 2012 at the Karolinska University Hospital Huddinge/Sweden.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In post-menopausal women, intravaginal oxytocin (vagitocin) 400 IU for seven weeks increased the vaginal maturation value.

    In plain wordsIn post-menopausal women, vaginal oxytocin at the higher dose improved the vaginal maturation value.

    Peptide
    Oxytocin
    Outcome
    IncreaseVaginal maturation value
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 IU · intravaginal · seven weeksAs given in this study (human).

    Measurements

    P value
    0.0002
    maturation value, 400 IU

    Source sentences

    Summary
    The percentage of superficial cells in the vaginal smears and the maturation values were significantly increased after seven weeks of treatment with vagitocin 400 IU (p = 0.0288 and p = 0.0002, respectively).
    1 context sentence
    Summary · context
    Sixty four post-menopausal women between February and June 2012 at the Karolinska University Hospital Huddinge/Sweden.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In post-menopausal women, intravaginal oxytocin (vagitocin) 100 IU for seven weeks lowered vaginal pH.

    In plain wordsIn post-menopausal women, vaginal oxytocin at the lower dose reduced vaginal pH.

    Peptide
    Oxytocin
    Outcome
    DecreaseVaginal pH
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    100 IU · intravaginal · seven weeksAs given in this study (human).

    Measurements

    P value
    0.02
    vaginal pH, 100 IU

    Source sentences

    Summary
    The vaginal pH decreased significantly after seven weeks of treatment with vagitocin 100 IU (p = 0.02).
    1 context sentence
    Summary · context
    Sixty four post-menopausal women between February and June 2012 at the Karolinska University Hospital Huddinge/Sweden.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In post-menopausal women, vagitocin 100 IU reduced the histological score of vaginal atrophy.

    In plain wordsIn post-menopausal women, vaginal oxytocin at the lower dose reduced the tissue-based vaginal atrophy score.

    Peptide
    Oxytocin
    Outcome
    DecreaseHistological vaginal atrophy score
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    100 IU · intravaginal · seven weeksAs given in this study (human).

    Measurements

    P value
    0.03
    atrophy score, 100 IU

    Source sentences

    Summary
    The scores of vaginal atrophy, according to the histological evaluation, were significantly reduced after administration of vagitocin 100 IU (p = 0.03).
    1 context sentence
    Summary · context
    Sixty four post-menopausal women between February and June 2012 at the Karolinska University Hospital Huddinge/Sweden.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In post-menopausal women, vagitocin 400 IU reduced the most bothersome symptom more than placebo after seven weeks.

    In plain wordsIn post-menopausal women, the higher vaginal oxytocin dose reduced the most bothersome symptom more than placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseMost bothersome symptom
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 IU · intravaginal · seven weeksAs given in this study (human).

    Measurements

    P value
    0.0089
    most bothersome symptom, 400 IU vs placebo

    Source sentences

    Summary
    The symptom experienced as the most bothersome was significantly reduced after seven weeks of treatment in the women receiving vagitocin 400 IU compared to women in the placebo group (p = 0.0089).
    1 context sentence
    Summary · context
    Sixty four post-menopausal women between February and June 2012 at the Karolinska University Hospital Huddinge/Sweden.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 2/3NCT05627791

Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman

Department of Medical Services Ministry of Public Health of Thailandn = 630 Nov 2022 to 28 Aug 2023

Vaginal Atrophy · Oxytocin Gel · Postmenopausal Women · Vaginal Maturation Index

Trial pageClinicalTrials.govUpdated 31 Aug 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.